Leerink analyst Puneet Souda downgraded Myriad Genetics (MYGN) to Market Perform from Outperform with a $21 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Settles Shareholder Lawsuits with Reforms
- Myriad announces Prequel Prenatal Screening can be performed at 8 weeks
- Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley
- Myriad Genetics price target lowered to $24 from $34 at Scotiabank
- Myriad Genetics expands access to at-home early fetal sex DNA test